Christopher A Jankowski

ID/Antimicrobial Stewardship Pharmacist. Tweets are my own and should not be associated in any context with current or past employers

[Ashlan J. Kunz Coyne @Ashlan_Kunz]

@ASMicrobiology Next up: Katharine Stott speaking my language! Hollow fiber infection models for antifungal evaluation.

[Ashlan J. Kunz Coyne @Ashlan_Kunz]

First up: Abhishek Das discussing his fascinating work with organelles and how antifungals impact immune cells @ASMicrobiology #ASMicrobe

[Ashlan J. Kunz Coyne @Ashlan_Kunz]

@DrNeilStone kicking off @ASMicrobiology Friday sessions with “Model Systems for Novel Antifungals - Moving Away From Mice” #ASMicrobe 🧫🐁

[ACCP INFD PRN @accpinfdprn]

💊 Can patients with a penicillin allergy safely receive piperacillin–tazobactam?

📊 The PIPPEN study found that 98% (187/191) of patients with a penicillin allergy tolerated piperacillin–tazobactam, including 100% of those with prior anaphylaxis.

https://t.co/yAd5szdoYB

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕💥🟢Utility of repeating blood cultures in detecting candidemia 7 days after initial negative cultures in 2 EHR datasets
Among 1386 candidemia episodes repeated blood culture detected 23% of episodes at HMH System & 45% in MIMIC-IV #idxposts https://t.co/5IZYciv18c

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

The real-world consequences are already apparent. Consider a hospitalised patient with ESBL-producing E.coli bacteremia with a meropenem MIC of 0.25 µg/mL; an organism that, despite its resistance phenotype, remains susceptible to meropenem by standard definitions. Under current IDSA guidance, this patient would receive meropenem 2 g EI every 8 hours, despite standard dose EI achieving well above the PD target for this organism. By definition, any susceptible Enterobacterales isolate, including ESBL-producing organisms, has a meropenem MIC≤1 µg/mL, a threshold at which standard-dose EI achieves excellent PTA.

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

Super interesting 👀
🆕💥🟢Evaluation of Sensititre YeastOne for antifungal susceptibility testing of Candida (Candidozyma) auris: misclassification of FKS1 mutants and overestimation of caspofungin resistance in a global collection of isolates #idxposts
https://t.co/GtkZ8ULbcK
1https://journals.asm.org/doi/10.1128/jcm.00130-26

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🔥Our article in EJHP is now published🔥🌟s @drgabx @BradSpellberg

“Universal high-dose meropenem for antimicrobial-resistant Gram-negative infections: evidence or overreach?”

We argue that the IDSA AMR guidance recommendation for universal high-dose meropenem (2 g IV q8h as 3h EI) for all infections other than uncomplicated cystitis is largely based on PK/PD extrapolation & expert opinion without supporting clinical outcomes data.
https://t.co/zhFI8w6Bws

[Paul Wischmeyer MD @Paul_Wischmeyer]

Hantavirus cardiopulmonary syndrome kills within 24h of hospital admission — and there's no antiviral. New Lancet ID review: what every ICU clinician needs to know.

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕💥🔴Nationwide prospective multicenter cohort/ GAMES
Effectiveness and safety of daptomycin versus vancomycin in methicillin-resistant Staphylococci left-side infective endocarditis. #idxposts #IEWiki
https://t.co/DJlJVF8TWt

[Mahdi Aleid | مهدي العيد @mahdi_aleid]

Understanding MICs and CLSI breakpoints is one of the most important skills in infectious diseases and antimicrobial stewardship.

A culture report should never stop at:
“Susceptible.”

Instead, we should ask:
• What is the MIC?
• Is it close to the breakpoint?
• Is the dosing optimized?
• Does the patient’s condition affect clinical success?

A great reminder that not all “susceptible” results are equally strong clinically.

#ClinicalPharmacy #InfectiousDiseases #AntimicrobialStewardship #CLSI #MIC #IDPharmacist #PharmacyResidency #CriticalCare #HealthcareEducation

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕💥🟢Overview of novel cefepime-based β-lactam/β-lactamase inhibitor combinations
🔺Cefepime/enmetazobactam
🔺Cefepime/taniborbactam
🔺Cefepime/zidebactam
🔺Cefepime/nacubactam #idxposts
https://t.co/AGhA2JyTbr

[Alí Sebastian Meza @AliSMV7]

Managing Pneumonia Due to Rare Non-Fermenting Gram-Negative Bacteria: Epidemiology, Risk Factors and Therapeutic Strategies

https://t.co/miu64xtcxF

[JAMA Internal Medicine @JAMAInternalMed]

💡 This Clinical Insights summarizes the pharmacological characteristics of dalbavancin and oritavancin and evaluates the clinical evidence supporting their use in infections beyond acute bacterial skin and skin structure infections. https://t.co/0Tq2jFfilU

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

💥Super interesting
Restoration of daptomycin sensitivity with adjunctive cefazolin is associated with C-terminal MprF mutations in MRSA bacteremia isolates
The seesaw effect
IC99 assay
SNAP is ongoing #IDXposts
https://t.co/uL7VJtAEQK

[NEJM @NEJM]

A new review provides an updated understanding of spinal epidural abscess and contemporary approaches to the treatment of patients with the illness. Read the full review: https://t.co/rMduCypW19

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🚨 Late Breaker – PROCALBAN OL RCT
🧪 PCT-guided de-escalation in sepsis (Bangladesh,n=532)
🎯Daily PCT→ stop Abx after 72h if <0.5 or ↓>80%
⏱️ Antibiotic duration nearly halved
• 4.7 vs 9d(p<0.0001)
🛡�� Safety preserved
• ⚰️ No difference in 28d mortality
#ESCMIDGlobal2026

[BITSCOPIC @Bitscopic]

Not all “susceptible” MSSA is the same. 🦠 Cefazolin inoculum effect showed up in 35.5% of isolates and was linked to more microbiologic failure, despite no mortality difference. A good stewardship reminder when MSSA isn’t clearing. https://t.co/onynbvgcxq

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕💥🔴In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without High-Level Aminoglycoside Resistance( HLAR) #IDXposts #IEWiki
https://t.co/unWltW5SZu

[The Lancet @TheLancet]

A new study, presented at @ESCMID, found that Nitrofurantoin was the most effective treatment and single-dose fosfomycin the least effective treatment for uncomplicated urinary tract infections (UTIs).

Explore the research: https://t.co/tlyp8fFWtC #ESCMIDGlobal2026 #ESCMID